tradingview.comOCT 272 min read$SENS

TD Cowen reiterates Buy rating on Senseonics Holdings, $15 price target

TD Cowen reiterated a Buy rating on Senseonics Holdings with a $15 price target, implying a 100.5% upside. The company is testing a next-gen CGM platform, aiming to reduce transmitter dependency, and plans to launch new products, potentially expanding its market share.

Original reporting

tradingview.com

Published Oct 27, 2026, 3:26 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 27, 2026, 3:36 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

TD Cowen reiterates Buy rating on Senseonics Holdings, $15 price target — source image — Source · tradingview.com

Decision brief

The 30-second read

$SENSBullishMed

Why it matters

Analyst upgrade could attract new capital and improve liquidity.

Market read

The new rating and price target may prompt short-term buying interest in SENS.

What to watch

Regulatory approval timeline and competition from larger CGM players.

Relevance 6/10Novelty 6/10Timing: today

Background

Senseonics is a small-cap medical device company developing CGM technology.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$SENSBullishHigh confidence

Context

TD Cowen reiterated a Buy rating on Senseonics Holdings and set a new $15 price target, implying a 100.5% upside.

Expected impact

likely upward pressure as investors price in the new target

Evidence & confidence

The rating change and target are fresh analyst actions that can influence short-term demand.

Market effects

Sector

Potential boost for the CGM/diabetes device sector as the upgrade highlights innovation.

Regional

Limited to U.S. biotech investors.

Global

Modest, primarily affecting niche medical device investors.

Counterpoint

What could challenge this read

The target may be overly optimistic given early-stage testing risks.

Key entities

Analyst
TD Cowen
Equity research firm providing the rating.
Company
Senseonics Holdings
Developer of the Eversense CGM platform.

Read at source ← All news

OCT 27

$SENSMedAI 8/10

Senseonics begins first human trial of Freedom CGM

Senseonics Holdings has started the first human trial for its Freedom CGM system, which transmits data directly to mobile devices without an external transmitter. The trial focuses on safety and functionality, with plans for a pivotal trial in 2027 and potential commercial release in 2028. The device builds on the Eversense 365 system, aiming to eliminate external components. Preclinical assessments were completed in Q2 2026.

medicaldevice-network.com2 min

OCT 7

$SYKMed

Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTech

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

tradingview.com3 min

SEP 14

$BBNXMedAI 8/10

Beta Bionics: FDA Clearance Of Mint Sets Stage For 2027 Patch Pump Launch

Beta Bionics (BBNX) received FDA clearance for its Mint patch pump, aiming for a Q1 2027 U.S. launch. The company also unveiled 3D Intelligence, a next-gen insulin dosing algorithm. Beta Bionics lowered its 2026 revenue outlook to $121M-$126M, citing potential revenue deferral. A partnership with Senseonics (SENS) was announced for integrating Eversense 365 with iLet Bionic Pancreas.

rttnews.com2 min

AUG 6

$SENSHigh

Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results

Senseonics Holdings, Inc. (SENS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results ● Generated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-year ● Raising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million,

SEC EDGAR 8-K7 min

OCT 28

$JMed

Jacobs (J) Selected for SFPUC’s $1B Wastewater Upgrade

Jacobs, in a joint venture with PCL Construction, was chosen by the San Francisco Public Utilities Commission for a $1B wastewater upgrade project. This selection supports Jacobs' focus on water and design-build programs, potentially boosting its regulated infrastructure backlog.

tradingview.com1 min